ARTICLE | Clinical News
Vectibix panitumumab: Phase III data
August 3, 2015 7:00 AM UTC
The open-label, international Phase III Study ‘0007 in about 377 chemorefractory mCRC patients with wild-type K-Ras (KRAS) exon 2 showed that 6 mg/kg IV Vectibix every 14 days plus best supportive ca...